RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.


Kenneth Rehder

Director, Innovation and Intellectual Property Development, Discovery – Science – Technology


PhD, Organic Chemistry, Michigan State University
BS, Chemistry, Purdue University

Ken Rehder, PhD, has more than 30 years of experience in synthetic organic chemistry, medicinal chemistry, and preclinical drug development. Dr Rehder is currently the director of Innovation and Intellectual Property Development for Discovery – Science - Technology. He is also principal investigator of the National Institute for Mental Health Chemical Synthesis and Drug Supply Program.

Dr. Rehder has served as project manager for two National Institute on Drug Abuse-funded translational medicine cooperative agreements, both of which resulted in RTI proprietary compounds reaching Phase 1 clinical trials. He has managed multiple collaborative drug discovery, medicinal chemistry, lead optimization, and preclinical-to-clinical projects, and has had managerial responsibility for multiple scientific departments.

Dr. Rehder's current interests include coordinating multidisciplinary, multiorganizational projects of significant scientific, logistical, and managerial complexity, particularly those involving intellectual property.

Get in Touch

To speak to this expert or inquire about RTI services, you can reach us at +1 919 541 6000 or use the contact form below. For media inquiries, please reach out to our Media Relations team at news@rti.org.

Blue background circle graphics